PTM Therapeutics, Inc.
Tuesday, February 27, 2024
Plymouth
Gastrointestinal
PTM Therapeutics is a pre-clinical stage antibody therapeutics company developing therapies through targeting post-translational modifications for the treatment of inflammatory bowel disease and solid tumors. Our lead antibody, PTM-001 targets inflamed, wounded intestinal mucosa and directly enhances wound healing. Moreover, PTM-001 has shown to also protect against further mucosal damage and is non-immune suppressive. Sector consensus indicates mucosal wound healing as an important, underserved drug mechanism for IBD therapies. PTM-001 represents a first-in-class opportunity for this unaddressed segment of the market
State
California
Country
United States
Website
https://www.ptmthera.com/
CEO/Top Company Official
Jennifer Cheng
Lead Product in Development
PTM-001 is a humanized monoclonal antibody therapeutic being developed for the treatment of IBD and solid tumors.
Development Phase of Primary Product
Pre-Clinical
Number Of Unlicensed Products
1-- We are actively seeking partners for our solid tumors using PTM-001 with as an antibody drug conjugate (ADC).
)
){kind=logo}
){kind=logo}
){kind=logo}
)
){kind=logo}
){kind=logo}
){kind=logo}
){kind=logo}
)
)
){kind=logo}
){kind=logo}
){kind=logo}
)
)
)
){kind=logo}